Table 5. Pharmacokinetics of irinotecan and SN-38.

	Irinotecan		SN-38
	Day 1 (test)	Day 15 (reference)	Day 1 (test)	Day 15 (reference)
Cmax (ng ml−1)
N	10	8	10	8
Median	2070	2120	20.4	15.1
Range	1590–3060	1760–2840	11.4–37.6	9.28–37.5
Tmax (h)
N	10	8	10	8
Median	1.5	1.54	1.5	1.6
Range	1.25–2.50	1.50–2.50	1.50–2.25	1.50–2.50
AUC(0–t) (ng ml−1·h)
N	10	8	10	8
Median	10 500	12 700	150	146
Range	7130–18 500	7040–17 900	35.4–380	42.5–380
AUC(0–∞) (ng ml−1·h)
N	9	8	10	7
Median	10 600	13 600	198	206
Range	7650–20 600	7330–20 400	102–550	64.7–508
T1/2 (h)
N	9	8	10	7
Median	6.43	6.21	13.6	15.7
Range	5.32–7.63	5.54–8.77	7.10–21.5	4.63–34.2
CL/f (l h−1)
N	9	8
Median	29.4	23.5	NC	NC
Range	16.4–47.0	15.6–46.8
Vz/f (l)
N	9	8
Median	297	212	NC	NC
Range	147–455	143–382
Ratio of Cmax test/reference
N		8		8
Median		0.973		1.11
Range		0.623–1.13		0.912–2.04
Ratio of AUC(0–∞) test/reference
N		8		7
Median		0.911		0.91
Range		0.577–1.08		0.825–1.58

Abbreviations: AUC_0–t=area under the concentration–time curve from time zero to the time of last observation; AUC_0–∞=area under the concentration–time curve from time zero to infinity; CL/f=apparent oral clearance; C_max=maximal concentration; NC=not calculated; t_1/2=apparent half-life; T_max=time of maximum concentration; Vz/f=apparent oral volume of distribution.

Pharmacokinetics of irinotecan and its active metabolite SN-38 following single 180 mg m⁻² doses on day 1 administered concomitantly with pimasertib (test) and following single 180 mg m⁻² doses on day 15 administered alone (reference).